Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Complete response and long-term survival (>20 years) of a child with tectal glioma: a case report.

Burzynski SR, Burzynski GS, Janicki TJ, Marszalek A.

Pediatr Neurosurg. 2015;50(2):99-103. doi: 10.1159/000369907. Epub 2015 Apr 22.

2.

The response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma.

Burzynski SR, Janicki TJ, Burzynski GS, Marszalek A.

Childs Nerv Syst. 2014 Dec;30(12):2051-61. doi: 10.1007/s00381-014-2401-z. Epub 2014 Apr 10.

3.

Long-term survival (>13 years) in a child with recurrent diffuse pontine gliosarcoma: a case report.

Burzynski SR, Janicki TJ, Burzynski GS, Marszalek A.

J Pediatr Hematol Oncol. 2014 Oct;36(7):e433-9. doi: 10.1097/MPH.0000000000000020.

4.

Stanislaw R. Burzynski, MD, PhD: novel cancer research and the fight to prove its worth.

Burzynski SR.

Altern Ther Health Med. 2012 May-Jun;18(3):54-61. No abstract available.

PMID:
22875562
5.

Treatments for astrocytic tumors in children: current and emerging strategies.

Burzynski SR.

Paediatr Drugs. 2006;8(3):167-78. Review.

PMID:
16774296
6.

Targeted therapy with antineoplastons A10 and AS2-1 of high-grade, recurrent, and progressive brainstem glioma.

Burzynski SR, Janicki TJ, Weaver RA, Burzynski B.

Integr Cancer Ther. 2006 Mar;5(1):40-7.

PMID:
16484713
7.

Long-term survival of high-risk pediatric patients with primitive neuroectodermal tumors treated with antineoplastons A10 and AS2-1.

Burzynski SR, Weaver RA, Janicki T, Szymkowski B, Jurida G, Khan M, Dolgopolov V.

Integr Cancer Ther. 2005 Jun;4(2):168-77.

PMID:
15911929
8.

Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma : a preliminary report.

Burzynski SR, Weaver RA, Lewy RI, Janicki TJ, Jurida GF, Szymkowski BG, Khan MI, Bestak M.

Drugs R D. 2004;5(6):315-26.

PMID:
15563234
9.

Aging: gene silencing or gene activation?

Burzynski SR.

Med Hypotheses. 2005;64(1):201-8.

PMID:
15533642
10.

Long-term survival and complete response of a patient with recurrent diffuse intrinsic brain stem glioblastoma multiforme.

Burzynski SR, Lewy RI, Weaver R, Janicki T, Jurida G, Khan M, Larisma CB, Paszkowiak J, Szymkowski B.

Integr Cancer Ther. 2004 Sep;3(3):257-61.

PMID:
15312271
11.

The present state of antineoplaston research (1).

Burzynski SR.

Integr Cancer Ther. 2004 Mar;3(1):47-58. Review.

PMID:
15035876
12.

Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report.

Burzynski SR, Lewy RI, Weaver RA, Axler ML, Janicki TJ, Jurida GF, Paszkowiak JK, Szymkowski BG, Khan MI, Bestak M.

Drugs R D. 2003;4(2):91-101.

PMID:
12718563
13.

Gene silencing--a new theory of aging.

Burzynski SR.

Med Hypotheses. 2003 Apr;60(4):578-83.

PMID:
12615527

Supplemental Content

Loading ...
Support Center